JP2007505640A - 排出可能なレポーターシステム - Google Patents
排出可能なレポーターシステム Download PDFInfo
- Publication number
- JP2007505640A JP2007505640A JP2006527469A JP2006527469A JP2007505640A JP 2007505640 A JP2007505640 A JP 2007505640A JP 2006527469 A JP2006527469 A JP 2006527469A JP 2006527469 A JP2006527469 A JP 2006527469A JP 2007505640 A JP2007505640 A JP 2007505640A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- reporter
- protein
- acid construct
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 126
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- 241001465754 Metazoa Species 0.000 claims abstract description 36
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 24
- 230000004913 activation Effects 0.000 claims abstract description 19
- 238000001727 in vivo Methods 0.000 claims abstract description 12
- 230000002503 metabolic effect Effects 0.000 claims abstract description 11
- 210000001124 body fluid Anatomy 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 238000012216 screening Methods 0.000 claims abstract description 9
- 230000002110 toxicologic effect Effects 0.000 claims abstract description 9
- 231100000027 toxicology Toxicity 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 164
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 230000009261 transgenic effect Effects 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 44
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 210000002700 urine Anatomy 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 230000006698 induction Effects 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229940015047 chorionic gonadotropin Drugs 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000001323 posttranslational effect Effects 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 230000007306 turnover Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 14
- 239000010839 body fluid Substances 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 24
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 22
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 22
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 22
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 22
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 22
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 20
- 102100026034 Protein BTG2 Human genes 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000758 substrate Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 108010091086 Recombinases Proteins 0.000 description 9
- 102000018120 Recombinases Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000037059 G2/M phase arrest Effects 0.000 description 6
- 108010052160 Site-specific recombinase Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 5
- 101710101078 Proton-activated chloride channel Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 229940127093 camptothecin Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003153 stable transfection Methods 0.000 description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000702191 Escherichia virus P1 Species 0.000 description 4
- 102000015212 Fas Ligand Protein Human genes 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 102100031786 Adiponectin Human genes 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102100021242 Dymeclin Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150033270 Gadd45a gene Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000933604 Homo sapiens Protein BTG2 Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101150032343 SFN gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 108091008004 TRAIL-RII Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 101150115889 al gene Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000020938 metabolic status Nutrition 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- AFWRJOYNLMVZQO-GMFATLNBSA-N (1r,2r,4as,8as)-1-[(1e,3e)-5-hydroxy-3-methylpenta-1,3-dienyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](/C=C/C(=C/CO)/C)[C@](C)(O)CC[C@H]21 AFWRJOYNLMVZQO-GMFATLNBSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 108010048028 Cyclophilin D Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241001235128 Doto Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001003102 Homo sapiens Hypoxia up-regulated protein 1 Proteins 0.000 description 1
- 101001130862 Homo sapiens Oligoribonuclease, mitochondrial Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 1
- 101000621427 Homo sapiens Wiskott-Aldrich syndrome protein Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100020755 Hypoxia up-regulated protein 1 Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 101100405118 Mus musculus Nr4a1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101001109695 Rattus norvegicus Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101100353123 Rattus norvegicus Ppp1r15a gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 1
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- ODMZDQKUHYGKKN-UHFFFAOYSA-N TCA C Natural products CC(CCCC(C)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3)C(=O)O ODMZDQKUHYGKKN-UHFFFAOYSA-N 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- -1 aryl hydrocarbon Chemical class 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000026618 small molecule metabolic process Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
一般的なその態様においては、本発明は、毒性の障害/ストレス、原発性のもしくは誘導された病気の状態、および/または改変された代謝状態の結果として生じる生化学的変化を非侵襲的に測定することを可能とする生物学的レポーターシステムを提供する。
−Glu−Gln−Lys−Leu−Ile−Ser−Glu−Glu−Asp−Leu−(配列番号1)
でもよく、または下記に示されるシミアンウイルスV5タンパク質(Southern et al J.Gen.Virol.72 1551−1557(1991))に由来するアミノ酸配列:
−Gly−Lys−Pro−Ile−Pro−Asn−Pro−Leu−Leu−Gly−Leu−Asp−Ser−Thr−(配列番号2)
でもよい。
1.発現カセット;
2.遍在的に発現するプロモーター(例えばホスホグリセリン酸キナーゼ(Soriano et al.,Cell 64 693−702(1991))の制御下で発現されるネガティブ選択マーカー(例えば単純ヘルペスウイルスチミジンキナーゼ(TK)遺伝子);および
3.DNA断片のいずれかの末端に位置する、バクテリオファージP1部位特異的組換え部位loxP(Baubonis et al.,Nuc.Acids.Res.21 2025−2029(1993))のコピーを二つ。
1.細胞をトランスフェクトすることまたは分泌/排出されるタンパク質をコードする核酸配列によるマウス受精卵の前核のマイクロインジェクションを行うステップ、ここで、このタンパク質は任意選択的に上記のペプチドまたはタンパク質のタグが付けられてもよく、任意で、マイクロインジェクションがなされた卵細胞またはトランスフェクトされたマウスのES細胞株を用いてもよい、
2.トランスフェクトされた細胞、細胞株またはトランスジェニック非ヒト動物に、遺伝子発現を改変させる代謝状態に変化を与えても与えなくてもよい刺激を与えるステップ、及び、
3.適切なアッセイを用いて、例えばELISA、RIA、質量分析、NMR、遠隔的方法などの検出方法を用いて、任意選択的にタグが付けられてもよい分泌/排出されるレポータータンパク質の発現レベルを測定するステップ。
1.化学物質の潜在的な毒作用について評価するための迅速で頑丈なインビボスクリーニング系を提供する。
2.毒性のメカニズムについての情報を提供する。このような情報を用いて選択プロセスから化合物を除去したり、または化合物に生じ得る修飾を示唆できるかもしれない。
3.化合物の結合の影響についての情報を与える。
4.異なる時間間隔での尿における単数(または複数)のレポーターのレベルを測定することによって、長期に亘るレポーター遺伝子の発現の変化のモニタリングを可能にする。
5.病原菌の感染に伴う遺伝子発現の変化の評価。
6.神経疾患、心臓病および代謝病に伴う遺伝子発現の変化の評価。
7.癌に伴う遺伝子発現の変化の評価。
8.例えばそのメカニズムが規定され理解されている毒作用にレポーター発現の特性を当てはめることによって、薬剤の標的を選択することの検証を可能とする情報を与える。
9.毒性の表現型、代謝の表現型または退化性の表現型を無効にすることを対象とする治療計画としての化合物を査定するための使用。
10.環境の変化および/または行動の変化に起因する遺伝子発現の変化の評価。
本発明の詳細な説明
まず、3’−オーバーハング配列を除去してBglIIリンカーを追加することによってBsmI制限酵素認識部位を変換し、次いでBglIIで切断することによって、GPIアンカーを欠く胎盤のアルカリホスファターゼ酵素の切断型で分泌される55.5kDのアルカリホスファターゼ(SEAP)をコードした配列を、pSEAP2−Basic(Clonetech)から切り出した。BglIIのSEAP断片を線状のpAHIR1(Campbell et al J.Cell Sci.109,2619−2625(1996))内に挿入し、それによって、8.5kbの5’−フランキング配列、第一のエクソンおよびイントロンならびに第二のエクソンに2548のラットのCyp1A1プロモーターが加えられたものの下流にこのレポーター遺伝子を位置させた。図1は、pCW2についてのプラスミドマップを示す。
(10%のFCS、2mMの1−グルタミンが追加されたDMEMにおいて5%のCO2で培養された)Hepa−C1C7細胞を、リン酸カルシウム共沈法を利用して、pCW2により一時的にまたは安定的に(pSVNeoと一緒に)トランスフェクトした。手短に言えば、5μgのプラスミド(+安定的なトランスフェクトのための1μgのpSVNeo)を塩化カルシウムおよびHEPES緩衝化塩溶液と混合して、細胞と一緒に5時間インキュベートをした後に分離されるリン酸カルシウム−DNA沈殿物を作製した。次いで、培地を新鮮な成長培地または選択培地(安定的なトランスフェクトのために400μg/mLのG418が追加された成長培地)と交換した。一時的にトランスフェクトされた細胞を6ウェルプレート内に注入し、3MCを増量して培養培地に溶解させたものでインキュベートした。安定的なトランスフェクトのために、個々のコロニーをプレート上で同定できると、すぐにそのコロニーを集めて2μg/mLの3MCでインキュベートした。3MCとのインキュベートから48時間後に、この培地についてのSEAP活性をアッセイした。
Cyp1A1プロモーター、SEAPおよびポリアデニル化配列を含むpCW2に由来する10kbのNotI制限断片をゲル電気泳動によって精製してプラスミドの配列を除去し、マウス受精卵(F1 C57/BL6×CBA)の雄性前核内に、1.5ng/μLの濃度で注入した。二細胞期に培養して生存している注入された卵細胞を、出産可能な偽妊娠した雌(F1)に移植した。トランスジェニックの状態についての遺伝子型の決定を、フォワードプライマー5’−CGCCAAGAACCTCATCATCT−3’(配列番号3)およびリバースプライマー5’−CGTCAATGTCCATGTTGGAG−3’(配列番号4)を認識するSEAPのcDNA配列を用いての、4〜6週齢の尾の生検材料(Whitelaw et al.Transgenic Res 1,3−13(1991))から抽出されたDNA上でのポリメラーゼ連鎖反応(PCR)によって行った。
Cyp1A1−SEAPの、インビボでの発現についての誘導を実証するために、マウスを3−メチルコラントレン(3MC)で処理した。ラットCYP1A1−LacZトランスジェニックマウスについて既に評価されたやり方(Campbell et al J.Cell Sci.109,2619−2625(1996))に従って、誘導を行った。Mazolaブランドのコーンオイルでの懸濁液として3MCを(少なくとも8週齢の)雌および雄のマウスの腹膜内に注入することによって投与した。試験動物は、トランスジェニック動物または同じ遺伝子型を有し年齢が適合する非トランスジェニック動物のいずれかであり、コーンオイル中の3−メチルコラントレン(3MC)を40mg/kg体重または0.4mg/kg体重のいずれかにて、24時間ごとに1回ずつ、連続して三回、腹膜内に注入することによって投与した。対照動物には、同量の担体のコーンオイルのみを投与した。最後の投与から24時間後に、全ての動物の首を脱臼して殺した。
・エピトープタグが付いたヒトβ−絨毛性ゴナドトロピンコード配列
(「myc」と指定された)次のオリゴヌクレオチド配列:
CTG CAG GAG CAG AAA CTC ATC TCT GAA GAG GAT CTG CTG CAG(配列番号5)を、天然のhCG配列のアミノ酸残基Val67およびGly68についてのコドンの間にある、ヒトβ−絨毛性ゴナドトロピン(hCG)コード配列の内部ループにおけるPstI制限酵素認識部位に挿入し、それによって、全配列が、内部の14アミノ酸のエピトープタグを保持するhCGをコードするようになる。
(14−3−3σとしても知られている)ストラチフィン(SFN)遺伝子のプロモーターは、DNAの損傷の結果として生じるG2/M期停止のマーカーである。SFN遺伝子は、γ−照射後またはドキソルビシンとしても知られているアドリアマイシンによる処理後のヒトの腫瘍に由来する細胞株において、G2/M期停止の間のp53依存性メカニズムを介して転写的に上方制御されることが示されている(Hermeking H.et al.,Molec.Cell 1:3−11,1997)。SFNの発現は、その発現によってG2/M期チェックポイントを経た進行が停止するという理由で、G2/M期停止に機能的に関与しているように見える(Hermeking H.et al.,Molec.Cell 1:3−11,1997)。さらに、腫瘍抑制タンパク質BRCA1に対応したSFNプロモーターの転写の活性化が生じ得る。このタンパク質が転写を活性化させる機能は、DNAの損傷によって活性化する(Somasundaran,K.,J.Cell Biol,88:1084−1091,2003)。SFNの誘導はp53発現の変化よりも先であるという事実(Aprelikova O.et al,J.Biol Chem,276:25647−25650,2001)、p53を欠損するHCC1937細胞におけるG2/M期停止およびSFNの誘導にとって、BRCA1の発現が必要かつ十分であるという事実(Yarden R.I.et al.,Nature Genetics,30:285−289,2002)は、誘導のこの経路がp53依存性であることを示唆する。従って、DNAの損傷によるSFNの誘導は、p53依存性経路およびp53独立性経路の両方を介して生じるようである(Hermeking H.et al.,Molec.Cell 1:3−11,1997;Aprelikova O.et al,J.Biol Chem,276:25647−25650,2001;Yarden R.I.et al.,Nature Genetics,30:285−289,2002)。
10kbの上流の調節プロモーターDNAと9kbの下流配列とを含むゲノムSFN配列のATG開始コドンの直後にhCG(myc)コード配列が挿入された人工遺伝子構築物を作製した。hCG(myc)配列は終止コドンを含むため、この構築物は、SFNプロモーターの制御下でhCG(myc)を発現することになる。Red/ET相同組換え系(Genebridges)を利用した組換えクローニングを用いてこのレポーター構築物を組み立てた。
フォワードSFN ATG GTC CTG TGT GTG TCA C(配列番号6)
リバースSFN CAG GGG AAC TTT ATT GAG A(配列番号7)
TGGTCCCAGGCAGCAGTTAGCCCGCCGCCCGCCTGTGTGTCCCCAGAGCCATGGAGATGTTCCAGGGGCTG(配列番号8)
LS−SFNamp
TAGCGTTCGGCCTGCTCTGCCAGCTTGGCCTTCTGGATCAGACTGGCTCTTTACCAATGCTTAATCAGTGA(配列番号9)
サブクローンフォワードSFN
TGCAGTGAGCCGAGATCTCGCCACTGCACTACTCCAGCCTGGGCGACAGAGCTTACGCCCCGCCCTGCCACTC(配列番号10)
サブクローンリバースSFN
GGATATGGGAGCCAGCCACATTCATACAGGGCACACATGAACACACACATGTCAAACATGAGAATTACAA(配列番号11)
前立腺腫瘍の細胞株PC3は、インビトロでは単層で増殖することが可能なp53−/−細胞株であり、先天的無胸腺ヌードマウスにおいて異種移植片として増殖する皮下の腫瘍を形成する。重要なことは、それが抗癌剤での処理後にG2/M期停止を経験する能力を有することである(Aranha O.et al.,Int.J.Oncol.22:787−794,2003)。
実施例6に記載のようにして、SFN−hCG(myc)−Ampレポーター構築物により安定的にトランスフェクトしたPC3細胞を、先天的無胸腺ヌードマウスにおける皮下の固形腫瘍として増殖させた。次いで、このマウスをG2/M期停止を導く機能を有する抗癌剤で処理した。この例示で選択された薬剤は、カンプトセシン(McDonald A.C.and Brown R.,Brit.J.Cancer,78:745−751,1998)であった。この実験のために、(hCGを発現または分泌しない)野生型のPC3細胞と、SFN−hCG(myc)−Ampレポーター構築物を含む安定的な細胞株とを用いた。野生型および改変されたPC3腫瘍細胞株を、10%〜15%の加熱不活性化させたウシ胎仔血清、2mMのL−グルタミン、ペニシリン(50IU/mL)、ストレプトマイシン(50μg/mL)を追加したRPMI培地で培養した。PC3/SFN細胞についての培養培地は、G418(200μg/mL)も含んでいた。加湿インキュベーター内で37℃、5%のCO2にて培養物をインキュベートした。細胞を回収し、集め、遠心分離にかけ、そして冷却した培地で再懸濁させた。腫瘍細胞注入溶液が、それぞれの細胞株に対して腫瘍細胞/培地およびMatrigelの50:50の混合物となるように、このものを等量の冷却したMatrigelと混合した。野生型PC3細胞またはトランスフェクトされたPC3細胞を、動物あたり2.5×106個注入した。全ての細胞株を、右腕の側面にのみ100μLの容量を注入した。
Claims (33)
- 生産または発現される細胞からタンパク質または産物として分泌可能であり、かつ全ての動物から排出可能であるレポータータンパク質をコードするレポーター遺伝子を含む核酸配列を含む核酸構築物。
- 分泌/排出可能なタンパク質または産物が、修飾された遺伝子の転写によって生産される、請求項1に記載の核酸構築物。
- 分泌/排出可能なタンパク質または産物が、レポーターの翻訳の増加によって生産される、請求項1に記載の核酸構築物。
- レポーターの翻訳の増加が、mRNAの安定性の向上または代謝回転の低下の結果である、請求項3に記載の核酸構築物。
- 分泌/排出可能なタンパク質または産物が、翻訳後の調節によって生産される、請求項1に記載の核酸構築物。
- 翻訳後の調節が、ポリユビキノン化の除去を介してのレポーターの安定性の向上、または小分子の代謝産物の蓄積もしくは排出の結果である、請求項5に記載の核酸構築物。
- エピトープタグの形式でもよいペプチドタグをさらに含む、請求項1〜6のいずれか1項に記載の核酸構築物。
- (i)分泌/排出されるタンパク質をコードする核酸配列および/または(ii)ペプチドタグをコードする核酸配列の上流にプロモーターエレメントをさらに含む、請求項1〜7のいずれか1項に記載の核酸構築物。
- 分泌/排出されるレポータータンパク質がSEAPである、請求項1〜8のいずれか1項に記載の核酸構築物。
- 構築物がCypA1プロモーターをさらに含む、請求項9に記載の核酸構築物。
- 分泌/排出されるレポータータンパク質が、修飾されたヒトβ絨毛性ゴナドトロピン(hCG)分子である、請求項1〜8のいずれか1項に記載の核酸構築物。
- 構築物がストラチフィン遺伝子のプロモーターをさらに含む、請求項11に記載の核酸構築物。
- hCGにタグが付けられている、請求項11または12のいずれかに記載の核酸構築物。
- hCGにmyc−タグが付けられている、請求項13に記載の核酸構築物。
- 分泌/排出されるレポータータンパク質/産物が、ホルモン分子、抗体および酵素分子からなる群より選択される、請求項1〜8のいずれかに記載の核酸構築物。
- ホルモン分子がFSHである、請求項15に記載の核酸構築物。
- 抗体がγ鎖または軽鎖(Bence Jones)タンパク質である、請求項15に記載の核酸構築物。
- 酵素分子がネコの尿のカルボキシラーゼである、請求項15に記載の核酸構築物。
- 請求項1〜18のいずれか一項に記載の核酸構築物の少なくとも一つによりトランスフェクトされた宿主細胞。
- 請求項1〜18のいずれか一項に記載の核酸構築物の少なくとも一つによりトランスフェクトされた細胞株。
- トランスジェニック非ヒト動物であって、前記非ヒト動物の細胞が、請求項1〜18のいずれか一項に記載の核酸構築物にコードされたタンパク質を発現するトランスジェニック非ヒト動物。
- 哺乳動物である、請求項21に記載のトランスジェニック非ヒト動物。
- 哺乳動物がマウスである、請求項22に記載のトランスジェニック非ヒト哺乳動物。
- 分泌/排出されるレポーター産物もしくはレポータータンパク質または分子が、尿、唾液、涙、乳汁、脳脊髄液および精液からなる群より選択される体液に排出される、請求項21〜23のいずれか1項に記載のトランスジェニック非ヒト動物。
- 分泌/排出されるレポーター産物もしくはレポータータンパク質または分子が、尿に排出される、請求項21〜24のいずれか1項に記載のトランスジェニック非ヒト動物。
- 分泌/排出されるレポーター部分が、60〜120kDa未満の範囲の比較的低分子量である、請求項19に記載の宿主細胞、請求項20に記載の細胞株または請求項21〜25のいずれか1項に記載のトランスジェニック非ヒト動物。
- 分泌/排出されるレポーター部分が、親水性の球状三次構造を有し、その生物活性が低く、そして容易に検出し定量できるように天然の分子と明瞭に区別できるものである、請求項19に記載の宿主細胞、請求項20に記載の細胞株または請求項21〜25のいずれか1項に記載のトランスジェニック非ヒト動物。
- 請求項1〜18に記載の二以上の核酸構築物を含む、請求項19に記載の宿主細胞、請求項20に記載の細胞株または請求項21〜25のいずれか1項に記載のトランスジェニック非ヒト動物。
- インビトロまたはインビボでの細胞における改変された代謝状態の変化に起因する遺伝子活性化事象を検出するための、請求項1〜18のいずれか一項に記載の核酸構築物の使用。
- 遺伝子活性化事象が、毒物学的ストレス、代謝状態の変化またはウイルス、細菌、真菌もしくは寄生虫の感染による誘導である、請求項29に記載の使用。
- 請求項1〜18のいずれか1項に記載の核酸構築物により安定的にトランスフェクトされた宿主細胞または請求項21〜25のいずれか1項に記載のトランスジェニック非ヒト動物をアッセイするステップを含む細胞における遺伝子活性化事象をインビトロまたはインビボで検出する方法であって、前記細胞または動物は、任意選択的に前記タンパク質にエピトープのタグが付けられた分泌/排出されるレポータータンパク質の発現によって合図される遺伝子活性化事象を受けている、方法。
- 請求項1〜18のいずれか一項に記載の核酸構築物によりトランスフェクトされたかまたは請求項1〜18のいずれか一項に記載の核酸構築物を保持する細胞、細胞株または非ヒト動物の使用を含む、細胞もしくは細胞株または非ヒト動物における毒物学的に誘導されたストレスをスクリーニングまたはモニタリングする方法。
- 請求項1〜18のいずれか一項に記載の核酸構築物によりトランスフェクトされたかまたは請求項1〜18のいずれか一項に記載の核酸構築物を保持する細胞、細胞株または非ヒト動物の使用を含む、ウイルス、細菌、真菌および寄生虫の感染をスクリーニングし特徴付けするための方法、または癌、炎症性疾患、心疾患、代謝病、神経疾患および遺伝子に基づく病気をスクリーニングするための方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322196.7A GB0322196D0 (en) | 2003-09-23 | 2003-09-23 | Excretable reporter systems |
PCT/GB2004/004054 WO2005028657A2 (en) | 2003-09-23 | 2004-09-23 | Excretable reporter systems |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007505640A true JP2007505640A (ja) | 2007-03-15 |
JP2007505640A5 JP2007505640A5 (ja) | 2007-11-08 |
Family
ID=29266458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006527469A Pending JP2007505640A (ja) | 2003-09-23 | 2004-09-23 | 排出可能なレポーターシステム |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070217999A1 (ja) |
EP (1) | EP1664313A2 (ja) |
JP (1) | JP2007505640A (ja) |
AU (1) | AU2004274707A1 (ja) |
CA (1) | CA2540155A1 (ja) |
GB (2) | GB0322196D0 (ja) |
WO (1) | WO2005028657A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009171920A (ja) * | 2008-01-28 | 2009-08-06 | Bio Regenerations:Kk | 抗癌剤のスクリーニング方法 |
JP2021514619A (ja) * | 2018-02-27 | 2021-06-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疾患の診断プローブとしての改変免疫細胞 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006261850B2 (en) * | 2005-06-22 | 2011-06-16 | Cxr Biosciences Limited | Reporter hepatocytes and other cells for drug screening and toxicity testing |
WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
EP2801622A1 (en) * | 2013-05-08 | 2014-11-12 | DeltaCell B.V. | Multi-tag reporter system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US641989A (en) * | 1899-05-13 | 1900-01-23 | George R Wallace | Paper-making machinery. |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0327960A1 (en) * | 1988-02-11 | 1989-08-16 | F. Hoffmann-La Roche Ag | Secretable forms of alkaline phosphatase |
DE19542051C2 (de) * | 1995-11-10 | 2000-03-23 | Asta Medica Ag | Gentechnisch veränderte tumorigene Zellinien und Verwendung derselben für die Testung von Antitumor-Wirkstoffen |
US6602657B1 (en) * | 1995-12-28 | 2003-08-05 | Tropix, Inc. | Multiple reporter gene assay |
US6319504B1 (en) * | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
ES2290964T3 (es) * | 1996-10-15 | 2008-02-16 | The Regents Of The University Of California | Modelos animales de la evolucion del cancer de prostata humano. |
CA2203613C (en) * | 1997-04-24 | 2008-01-15 | Navneet K. Ahluwalia | Secreted .alpha.-amylase as a reporter gene |
WO2000079264A1 (en) * | 1999-06-24 | 2000-12-28 | Baylor College Of Medicine | System and method to detect compounds and mutations that upregulate and downregulate expression of nucleotide sequences |
GB9925125D0 (en) * | 1999-10-22 | 1999-12-22 | Novartis Ag | Organic compounds |
KR100408429B1 (ko) * | 2000-01-24 | 2003-12-06 | 한미약품 주식회사 | 유즙 중에 인간 과립구 콜로니 자극인자를 생산하는형질전환 흑염소 |
KR100358754B1 (ko) * | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
US6419896B1 (en) * | 2000-03-03 | 2002-07-16 | Bert Vogelstein | Non-invasive approach for assessing tumors in living animals |
US7176187B2 (en) * | 2001-02-15 | 2007-02-13 | Board Of Regents, The University Of Texas System | Fusion proteins based upon somatostatin receptors |
DE60117641T2 (de) * | 2001-06-22 | 2007-01-11 | Aventis Pharma S.A. | Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide |
GB0217402D0 (en) * | 2002-07-26 | 2002-09-04 | Roslin Inst Edinburgh | Multi-reporter gene model for toxicological screening |
GB0308150D0 (en) * | 2003-04-09 | 2003-05-14 | Cxr Biosciences Ltd | Method of determining xenograft responses |
-
2003
- 2003-09-23 GB GBGB0322196.7A patent/GB0322196D0/en not_active Ceased
-
2004
- 2004-09-23 JP JP2006527469A patent/JP2007505640A/ja active Pending
- 2004-09-23 EP EP04768598A patent/EP1664313A2/en not_active Withdrawn
- 2004-09-23 WO PCT/GB2004/004054 patent/WO2005028657A2/en active Application Filing
- 2004-09-23 US US10/572,975 patent/US20070217999A1/en not_active Abandoned
- 2004-09-23 CA CA002540155A patent/CA2540155A1/en not_active Abandoned
- 2004-09-23 GB GB0421157A patent/GB2406337B/en not_active Expired - Fee Related
- 2004-09-23 AU AU2004274707A patent/AU2004274707A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US641989A (en) * | 1899-05-13 | 1900-01-23 | George R Wallace | Paper-making machinery. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009171920A (ja) * | 2008-01-28 | 2009-08-06 | Bio Regenerations:Kk | 抗癌剤のスクリーニング方法 |
JP2021514619A (ja) * | 2018-02-27 | 2021-06-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疾患の診断プローブとしての改変免疫細胞 |
Also Published As
Publication number | Publication date |
---|---|
CA2540155A1 (en) | 2005-03-31 |
WO2005028657A3 (en) | 2005-07-21 |
GB0421157D0 (en) | 2004-10-27 |
WO2005028657A2 (en) | 2005-03-31 |
GB2406337A (en) | 2005-03-30 |
EP1664313A2 (en) | 2006-06-07 |
GB0322196D0 (en) | 2003-10-22 |
AU2004274707A1 (en) | 2005-03-31 |
GB2406337B (en) | 2007-03-07 |
US20070217999A1 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4318736B2 (ja) | ヒト抗体遺伝子を発現する非ヒト動物とその利用 | |
US20040250307A1 (en) | Transgenic avian species for making human and chimeric antibodies | |
AU2008322038B2 (en) | Mammalian artificial chromosome vector comprising human cytochrome P450 gene (cluster) and non-human mammalian animal retaining the same | |
JP2009055911A (ja) | 薬理学的及び毒性学的研究のための非ヒトトランスジェニック動物 | |
US7745688B2 (en) | Model mouse of Alzheimer's disease expressing FAD APP 716 and use thereof | |
US7582741B2 (en) | Conditional disruption of dicer1 in cell lines and non-human mammals | |
WO2020240876A1 (ja) | エクソンヒト化マウス | |
US20110035816A1 (en) | Genetically Modified Rat Models for Drug Metabolism | |
KR20080016687A (ko) | 포유 동물 유래의 Vasa 호몰로그 유전자의 프로모터배열을 포함하는 발현 벡터 및 그 이용 | |
JP2007505640A (ja) | 排出可能なレポーターシステム | |
US20090013417A1 (en) | Transgenic Animals for Assessing Drug Metabolism and Toxicity in Man | |
JP2001211782A (ja) | tob遺伝子欠損ノックアウト非ヒト哺乳動物 | |
EP1731601B1 (en) | INACTIVE Ca2+/CALMODULIN-DEPENDENT PROTEIN KINASE II alpha KNOCKIN ANIMAL AND KNOCKIN CELL OF THE SAME | |
WO2017175745A1 (ja) | 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法 | |
JP4931153B2 (ja) | 糖尿病モデル動物 | |
US7238797B2 (en) | Nucleic acid encoding a pig heat shock protein 70 | |
US20140053288A1 (en) | Epo knockout gfp anemic mouse | |
JP2007312792A (ja) | キメラ動物およびその作製法 | |
US20030208785A1 (en) | Transgenic pig containing heat shock protein 70 transgene | |
US20090007283A1 (en) | Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein | |
Stevens | Analysis of putative mutants produced by genetrap technology | |
JP2001145487A (ja) | tob遺伝子欠損動物由来の細胞 | |
WO2007127254A2 (en) | Compositions and methods for generating transgenic animals | |
JPH11313576A (ja) | キメラ動物およびその作製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100528 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100714 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101126 |